Michael Dougherty
Director/Board Member presso Altherx, Inc.
Patrimonio netto: 17 871 $ in data 31/03/2024
Profilo
Michael R.
Dougherty currently works at AltheRx, Inc., as Director from 2013 and Viralclear Pharmaceuticals, Inc., as Director from 2020.
Mr. Dougherty also formerly worked at Genaera Corp., as President & Chief Executive Officer from 1998 to 2000, Adolor Corp., as President, Chief Executive Officer & Director from 2006 to 2011, Kalidex Pharmaceuticals, Inc., as Chief Executive Officer & Director in 2012, Celator Pharmaceuticals, Inc., as Executive Chairman from 2015 to 2016, Idera Pharmaceuticals, Inc., as Independent Director, Shire ViroPharma, Inc., as Independent Director from 2004 to 2014, Marinus Pharmaceuticals, Inc., as Independent Director from 2017 to 2022, Cempra Pharmaceuticals, Inc., as Director, Cempra, Inc., as Independent Director from 2013 to 2017, Trevena, Inc., as Independent Director from 2013 to 2023, Foundation Medicine, Inc., as Independent Director from 2016 to 2018, Aviragen Therapeutics, Inc., as Independent Non-Executive Director from 2013 to 2018, Aceragen, Inc., as Independent Director from 2022 to 2023, Centocor, Inc., as Chief Financial Officer & Senior Vice President, and Genomics Collaborative, Inc., as President & Chief Operating Officer from 2000 to 2002.
Mr. Dougherty received his undergraduate degree in 1980 from Villanova University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
ACERAGEN, INC.
0.26% | 19/07/2023 | 22 067 ( 0.26% ) | 17 742 $ | 31/07/2023 |
TREVENA, INC.
0.00% | 15/06/2023 | 280 ( 0.00% ) | 129 $ | 31/03/2024 |
Posizioni attive di Michael Dougherty
| Società | Posizione | Inizio |
|---|---|---|
Altherx, Inc.
 Altherx, Inc. Medical/Nursing ServicesHealth Services Altherx, Inc. operates as a clinical development company. The company was founded on May 11, 2010 and is headquartered in Glenmoore, PA. | Director/Board Member | 30/05/2013 |
Viralclear Pharmaceuticals, Inc.
 Viralclear Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ViralClear Pharmaceuticals, Inc. manufactures anti-viral drug. The company is headquartered in Westport, CT. | Director/Board Member | 28/05/2020 |
Precedenti posizioni note di Michael Dougherty
| Società | Posizione | Fine |
|---|---|---|
| TREVENA, INC. | Director/Board Member | 14/09/2023 |
| ACERAGEN, INC. | Chairman | 01/09/2022 |
| MARINUS PHARMACEUTICALS, INC. | Director/Board Member | 13/11/2022 |
| FOUNDATION MEDICINE INC | Director/Board Member | 31/07/2018 |
Aviragen Therapeutics, Inc.
 Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Director/Board Member | 01/02/2018 |
Formazione di Michael Dougherty
| Villanova University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| MARINUS PHARMACEUTICALS, INC. | Health Technology |
| TREVENA, INC. | Health Technology |
| Aziende private | 15 |
|---|---|
Centocor, Inc.
 Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | Health Technology |
Genaera Corp.
 Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | Health Technology |
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
Shire ViroPharma, Inc.
 Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Health Technology |
Adolor Corp.
 Adolor Corp. BiotechnologyHealth Technology Adolor Corp. is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. The company develops and commercializes of novel opioid receptor-targeted therapeutics designed to maintain or improve pain relief and reduce opioid-related side effects. Its commercial product ENTEREG is a small molecule, peripherally acting mu opioid receptor antagonist intended to block the adverse side effects of opioid analgesics like morphine, on the gastrointestinal tract without interfering with central nervous system and mediated analgesia. The company was founded in 1993 and is headquartered in Exton, PA. | Health Technology |
Celator Pharmaceuticals, Inc.
 Celator Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Celator Pharmaceuticals, Inc. engages in the research and development of biopharmaceutical products. The company was founded by Lawrence David Mayer, and Marcel B. Bally in 1999 and is headquartered in Ewing, NJ. | Health Technology |
Cempra Pharmaceuticals, Inc.
 Cempra Pharmaceuticals, Inc. BiotechnologyHealth Technology Cempra Pharmaceuticals, Inc. develops medicines for treating drug-resistant bacterial infections. The firm's antibacterial products, both in clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community. The company was founded by Prabhavathi B. Fernandes IN 2006 and is headquartered in Chapel Hill, NC. | Health Technology |
Cempra, Inc.
 Cempra, Inc. Pharmaceuticals: MajorHealth Technology Cempra, Inc. engages as a clinical-stage pharmaceutical company, which focuses on the development of antibacterials to meet critical medical needs. Its products include; Solithromycin and Taksta. The company was founded by Prabhavathi B. Fernandes on November 18, 2005 and is headquartered in Chapel Hill, NC. | Health Technology |
Kalidex Pharmaceuticals, Inc.
 Kalidex Pharmaceuticals, Inc. BiotechnologyHealth Technology Kalidex Pharmaceuticals, Inc. develops antibiotics for the treatment of serious infections. Its lead development candidate KPI-10 is a next-generation fluoroquinolone against a range of important gram-negative and gram-positive pathogens including multi-drug resistant strains and isolates resistant to currently available fluoroquinolones. The company was founded in 2010 by James Ge, Vernocn Jiang and George H. Talbot and is headquartered in Menlo Park, CA. | Health Technology |
Genomics Collaborative, Inc.
 Genomics Collaborative, Inc. Medical SpecialtiesHealth Technology Genomics Collaborative, Inc. provides clinical samples and applies human genetics to target validation for drug discovery. The company is based in Cambridge, MA. The company was founded by Phyllis I. Gardner and Edward E. Harlow. Genomics Collaborative was acquired by BioServe Biotechnologies Ltd., a SUB of ReproCELL, Inc. from SeraCare Life Sciences, Inc. on May 29, 2007 for $2 million. | Health Technology |
Foundation Medicine, Inc.
 Foundation Medicine, Inc. Medical/Nursing ServicesHealth Services Foundation Medicine, Inc. is a molecular information company, which engages in the provision of information on clinical treatment decisions for patients with cancer. The company was founded on January 10, 2010 and is headquartered in Cambridge, MA. | Health Services |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Health Technology |
Altherx, Inc.
Altherx, Inc. Medical/Nursing ServicesHealth Services Altherx, Inc. operates as a clinical development company. The company was founded on May 11, 2010 and is headquartered in Glenmoore, PA. | Health Services |
Viralclear Pharmaceuticals, Inc.
Viralclear Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ViralClear Pharmaceuticals, Inc. manufactures anti-viral drug. The company is headquartered in Westport, CT. | Health Technology |
| Aceragen, Inc. |
- Borsa valori
- Insiders
- Michael Dougherty
